Cargando…

Editorial Comment on Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer

Detalles Bibliográficos
Autor principal:	Tanaka, Nobumichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249641/ https://www.ncbi.nlm.nih.gov/pubmed/35795116 http://dx.doi.org/10.1002/iju5.12454

Ejemplares similares

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Toriumi, Ren, et al.
Publicado: (2022)

Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants
por: Butler, Wayne M., et al.
Publicado: (2021)

Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervals—Impact of a Hydrogel Spacer and Prostate Volume
por: Haddad, Hathal, et al.
Publicado: (2023)

The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
por: Tanaka, Nobumichi
Publicado: (2023)

Salvage high-dose-rate brachytherapy for prostate cancer persistence after brachytherapy: repeated use of a polyethylene glycol hydrogel spacer
por: Hepp, Rodrigo, et al.
Publicado: (2018)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Seed lost to perineum from hydrogel spacer after brachytherapy for prostate cancer
por: Nakiri, Makoto, et al.
Publicado: (2023)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

Impact of hydrogel and hyaluronic acid rectal spacer on rectal dosimetry and toxicity in low-dose-rate prostate brachytherapy: a multi-institutional analysis of patients’ outcomes
por: Lin, Yuan-Hong, et al.
Publicado: (2021)

Hydrogel spacer shrinkage during external-beam radiation therapy following low-dose-rate brachytherapy for high-risk prostate cancer: a case series
por: Kubo, Katsumaro, et al.
Publicado: (2021)

The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

A Novel Murine Model of a High Dose Brachytherapy-Induced Actinic Proctitis
por: Leite, Carlos Heli Bezerra, et al.
Publicado: (2022)

Editorial Comment: Translational research in urology: nutricion and prostate
por: Favorito, Luciano A.
Publicado: (2021)

Editorial comment: Renal denervation
por: Schmieder, Roland E., et al.
Publicado: (2021)

Editorial Comment to Tri‐modality therapy with i‐125 brachytherapy, external beam radiation therapy, and short‐term hormone therapy for high‐risk prostate cancer after holmium laser enucleation of the prostate
por: Tomisaki, Ikko
Publicado: (2022)

Editorial Comment to Granulomatous prostatitis with high suspicion of prostatic adenocarcinoma on radiological imaging
por: Sekito, Takanori, et al.
Publicado: (2021)

Focal salvage high-dose-rate brachytherapy with implantable rectum spacer for locally recurrent prostate cancer after initial low-dose-rate with grade 3 rectal toxicity
por: Opbroek, Thirza, et al.
Publicado: (2023)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Editorial Comment
por: Madbouly, Khaled
Publicado: (2011)

EDITORIAL COMMENT
por: Mladenov, Dimitar
Publicado: (2013)

EDITORIAL COMMENT
por: Gibas, Artur
Publicado: (2013)

EDITORIAL COMMENT
por: Salagierski, Maciej
Publicado: (2013)

EDITORIAL COMMENT
por: Tiu, Albert, et al.
Publicado: (2013)

EDITORIAL COMMENT
por: Poletajew, Sławomir, et al.
Publicado: (2013)

EDITORIAL COMMENT
por: Oszukowska, Elżbieta
Publicado: (2013)

EDITORIAL COMMENT
por: Matuszewski, Marcin
Publicado: (2013)

EDITORIAL COMMENT
por: Świniarski, Piotr Paweł
Publicado: (2013)

EDITORIAL COMMENT
por: Apoznański, Wojciech
Publicado: (2013)

Editorial Comment
por: Goel, Apul
Publicado: (2023)

Editorial Comment to Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma
por: Funahashi, Yasuhito
Publicado: (2020)

Editorial Comment to Microscopic pulmonary tumor embolism from adenocarcinoma of the prostate
por: Iguchi, Taro, et al.
Publicado: (2020)

Editorial Comment to Undifferentiated pleomorphic sarcoma of the prostate in a young man
por: Ochi, Atsuhiko
Publicado: (2020)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Localized prostate cancer with pelvic arteriovenous malformation treated with low‐dose‐rate brachytherapy after transcatheter embolization: Two case reports
por: Owari, Takuya, et al.
Publicado: (2019)

Secondary Amyloidosis Presenting as Ischemic Proctitis
por: Hashmi, Saad, et al.
Publicado: (2021)

Case Report: Role of an Iodinated Rectal Hydrogel Spacer, SpaceOAR Vue™, in the Context of Low-Dose-Rate Prostate Brachytherapy, for Enhanced Post-Operative Contouring to Aid in Accurate Implant Evaluation and Dosimetry
por: Gross, Andrew, et al.
Publicado: (2021)

Polyethylene glycol-based hydrogel rectal spacers for prostate brachytherapy: a systematic review with a focus on technique
por: Vaggers, S., et al.
Publicado: (2020)

Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
por: Kunogi, Hiroaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8jmo8hv6gi35nlk7ri1snleamk